Search Results - "Rotmensch, J."

Significant delay in the treatment of endometrial cancer based on race and insurance status by Dolly, D.R, Mihai, A, Fogg, L, Guirguis, A, Yordan, E.L, Rotmensch, J

Get full text

The clinical relevance of a chemo response assay for treatment of epithelial ovarian cancer by Dolly, D.R, Dewdney, S.B, Rotmensch, J, Bitterman, P, Barua, A

Get full text

A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study by Sill, M, Thaker, P, De Geest, K, Street, D, McGuire, W, Rotmensch, J

Get full text

A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group (GOG) study by Bender, D.P, Sill, M, Lankes, H, Darus, C.J, Delmore, J, Rotmensch, J, Gray, H.J, Mannel, R.S, Schilder, J.M, Leslie, K.K, Reyes, H.D, Hunter, M, McCourt, C.K, Samuelson, M

Get full text

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study by Alvarez, E, Brady, W, Walker, J, Rotmensch, J, Zhou, X, Kendrick, J, Yamada, S, Aghajanian, C

Get full text

Controversies associated with cervical cytologic screening: a physician's view by Rotmensch, J

Get full text

An α-Fetoprotein-Producing Hepatoid Adenocarcinoma of the Endometrium by Adams, S.F., Yamada, S.D., Montag, A., Rotmensch, J.R.

“…Background. Hepatoid adenocarcinomas are tumors that arise outside the liver but resemble hepatic tissue and produce α-fetoprotein. These neoplasms have been…”
Get full text

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors by Eng, C., Mauer, A. M., Fleming, G. F., Bertucci, D., Rotmensch, J., Jacobs, R. H., Ratain, M.J.

“…Summary Background: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor…”
Get full text

Synchronous ovarian and endometrial malignancies by CASTRO, Iris M, CONNELL, Philip P, WAGGONER, Steven, ROTMENSCH, Jacob, MUNDT, Arno J

“…Synchronous ovarian primaries are infrequently found in patients with endometrial cancer. Although numerous investigators have examined the characteristics of…”
Get full text

Intraperitoneal administration of alpha-emitting isotopes by Dewdney, S.B

Get full text

Ultrasound guidance for placement of difficult intracavitary implants by Rotmensch, J, Waggoner, S E, Quiet, C

“…Placement of a radiation implant in patients with cervical cancer may be difficult because of distortion of the canal by tumor or fibrosis from previous…”
Get more information

Radionuclide Therapy for the Treatment of Microscopic Ovarian Carcinoma:  An Overview by Whitlock, Jenny L, Roeske, John C, Dietz, Mark L, Straus, Chris M, Hines, John J, Horwitz, E. Philip, Reba, Richard C, Rotmensch, Jacob

“…Cancer comprises a group of diseases characterized by the uncontrolled growth of abnormal cells that spread from the anatomical site of origin. For many types…”
Get full text

Uterine carcinosarcoma: Immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets by Cimbaluk, David, Rotmensch, Jacob, Scudiere, Jennifer, Gown, Allen, Bitterman, Pincas

“…Abstract Objective Carcinosarcoma of the uterus is a highly aggressive tumor containing both malignant epithelial and spindle (mesenchymal) components. Because…”
Get full text

Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies by Mundt, Arno J, Lujan, Anthony E, Rotmensch, Jacob, Waggoner, Steven E, Yamada, S Diane, Fleming, Gini, Roeske, John C

“…To describe our initial clinical experience with intensity-modulated whole pelvic radiotherapy (IM-WPRT) in women with gynecologic malignancies. Between…”
Get more information

In vitro and in vivo studies on the development of the α-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma by Rotmensch, Jacob, Whitlock, Jenny L., Schwartz, Jeffrey L., Hines, John J., Reba, Richard C., Harper, Paul V.

“…OBJECTIVE: Our objective was to develop the α-emitting radionuclide bismuth 212 for possible intraperitoneal use against microscopic ovarian cancer. STUDY…”
Get full text

Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies by Brixey, Clark J, Roeske, John C, Lujan, Anthony E, Yamada, S Diane, Rotmensch, Jacob, Mundt, Arno J

“…To evaluate the impact of intensity-modulated whole pelvic radiotherapy (IM-WPRT) on acute hematologic toxicity (HT) in gynecology patients. Between February…”
Get more information

Malignant transition of uterine leiomyomata by Rotmensch, J, Bosnyak, S, Montag, A

Get more information

Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies by Roeske, J C, Lujan, A, Rotmensch, J, Waggoner, S E, Yamada, D, Mundt, A J

“…To evaluate the ability of intensity-modulated radiation therapy (IMRT) to reduce the volume of small bowel irradiated in women with gynecologic malignancies…”
Get more information

Re: Response of Aleukemic Granulocytic Sarcoma to All-trans-retinoic Acid Plus Interferon Alfa-2a by Fleming, Gini F., Waggoner, S. E., Wu, S., Rotmensch, J., Conley, B. A.

“…Fleming et al report on two patients treated with a regimen of continuous oral all-trans-retinoic acid (ATRA) at a dose of 150 mg/m2 per day for days 1-29…”
Get full text

Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy by Lujan, Anthony E, Mundt, Arno J, Yamada, S Diane, Rotmensch, Jacob, Roeske, John C

“…To evaluate intensity-modulated whole pelvis radiotherapy (IM-WPRT) (with bone marrow [BM] as a planning constraint) as a means to reduce the volume of pelvic…”
Get more information